Mesoblast (MESO) has released an update.
Mesoblast Limited has announced the cessation of 80,000 options due to the lapse of conditional rights, as conditions for these securities were not or could not be satisfied by the deadline of March 31, 2024. No consideration will be paid for the cessation. Following this change, the company’s updated issued capital includes over 1.14 billion ordinary shares and various classes of unquoted equity securities.
For further insights into MESO stock, check out TipRanks’ Stock Analysis page.
